OBJECTIVE: The aim of the study was to determine the prevalence and risk factors for HIV-associated fatigue in the era of highly active antiretroviral therapy (HAART). METHODS: A cross-sectional survey of 100 stable HIV-infected out-patients was carried out. Severity of fatigue was measured using the Fatigue Impact Scale (FIS). Symptoms of orthostatic intolerance (dysautonomia) were evaluated using the Orthostatic Grading Scale (OGS). Data for HIV-infected patients were compared with those for 166 uninfected controls and 74 patients with chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (encephalopathy) (ME). RESULTS: Ninety-one per cent of HIV-infected patients were on HAART and 78% had suppressed plasma HIV viral load (≤ 40 HIV-1 RNA copies/mL). Fifty-one per cent of HIV-infected patients reported excessive symptomatic fatigue (FIS ≥ 40), and 28% reported severe fatigue symptoms (FIS ≥ 80). The mean FIS score among HIV-infected patients was 50.8 [standard deviation (SD) 41.9] compared with 13.0 (SD 17.6) in uninfected control subjects, and 92.9 (SD 29.0) in CFS patients (P < 0.001 for comparison of HIV-infected patients and uninfected controls). Among HIV-infected patients, fatigue severity was not significantly associated with current or nadir CD4 lymphocyte count, HIV plasma viral load, or whether on HAART. Prior dideoxynucleoside analogue (d-drug) exposure (P = 0.016) and the presence of clinical lipodystrophy syndrome (P = 0.011) were associated with fatigue. Additionally, fatigue severity correlated strongly with symptomatic orthostatic intolerance (r = 0.65; P < 0.001). CONCLUSIONS: Fatigue is very common and often severe in HIV-infected out-patients, despite viral suppression and good immune function. In a subgroup of patients, prior d-drug exposure may contribute to fatigue, suggesting a metabolic basis. Dysautonomia may also drive fatigue associated with HIV infection, as in other chronic diseases, and CFS/ME, and should be further evaluated with the potential for a shared therapeutic approach.
OBJECTIVE: The aim of the study was to determine the prevalence and risk factors for HIV-associated fatigue in the era of highly active antiretroviral therapy (HAART). METHODS: A cross-sectional survey of 100 stable HIV-infected out-patients was carried out. Severity of fatigue was measured using the Fatigue Impact Scale (FIS). Symptoms of orthostatic intolerance (dysautonomia) were evaluated using the Orthostatic Grading Scale (OGS). Data for HIV-infected patients were compared with those for 166 uninfected controls and 74 patients with chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (encephalopathy) (ME). RESULTS: Ninety-one per cent of HIV-infected patients were on HAART and 78% had suppressed plasma HIV viral load (≤ 40 HIV-1 RNA copies/mL). Fifty-one per cent of HIV-infected patients reported excessive symptomatic fatigue (FIS ≥ 40), and 28% reported severe fatigue symptoms (FIS ≥ 80). The mean FIS score among HIV-infected patients was 50.8 [standard deviation (SD) 41.9] compared with 13.0 (SD 17.6) in uninfected control subjects, and 92.9 (SD 29.0) in CFS patients (P < 0.001 for comparison of HIV-infected patients and uninfected controls). Among HIV-infected patients, fatigue severity was not significantly associated with current or nadir CD4 lymphocyte count, HIV plasma viral load, or whether on HAART. Prior dideoxynucleoside analogue (d-drug) exposure (P = 0.016) and the presence of clinical lipodystrophy syndrome (P = 0.011) were associated with fatigue. Additionally, fatigue severity correlated strongly with symptomatic orthostatic intolerance (r = 0.65; P < 0.001). CONCLUSIONS: Fatigue is very common and often severe in HIV-infected out-patients, despite viral suppression and good immune function. In a subgroup of patients, prior d-drug exposure may contribute to fatigue, suggesting a metabolic basis. Dysautonomia may also drive fatigue associated with HIV infection, as in other chronic diseases, and CFS/ME, and should be further evaluated with the potential for a shared therapeutic approach.
Authors: Julie Barroso; Jane Leserman; James L Harmon; Bradley Hammill; Brian W Pence Journal: J Pain Symptom Manage Date: 2015-02-18 Impact factor: 3.612
Authors: Christopher N Schmickl; Naa-Oye Bosompra; Pamela N DeYoung; Dillon Gilbertson; Jeremy E Orr; Atul Malhotra; Igor Grant; Sonia Ancoli-Israel; Maile Karris Young; Robert L Owens Journal: J Clin Sleep Med Date: 2022-07-01 Impact factor: 4.324
Authors: Jeremy E Orr; Bradley A Edwards; Christopher N Schmickl; Maile Karris; Pamela N DeYoung; Chantal Darquenne; Rebecca Theilmann; Sonia Jain; Atul Malhotra; Charles B Hicks; Robert L Owens Journal: J Appl Physiol (1985) Date: 2021-10-21
Authors: Kelly Jensen; Young Ah Goo; Anella Yahiaoui; Sundeep Bajwa; Dave Goodlett; Jim Russo; Joachim Voss Journal: Biol Res Nurs Date: 2013-07-16 Impact factor: 2.522
Authors: Ellen T M Laan; Jan M Prins; Rik H W van Lunsen; Pythia T Nieuwkerk; Marian A F Nievaard-Boon Journal: Sex Med Date: 2018-12-03 Impact factor: 2.491
Authors: Sverker Johansson; Anders Kottorp; Kathryn A Lee; Caryl L Gay; Anners Lerdal Journal: Health Qual Life Outcomes Date: 2014-02-22 Impact factor: 3.186
Authors: Brendan A I Payne; Kieren G Hollingsworth; Joanne Baxter; Edmund Wilkins; Vincent Lee; D Ashley Price; Michael Trenell; Patrick F Chinnery Journal: PLoS One Date: 2014-01-07 Impact factor: 3.240